Free tool
FAERS Monitor: Folotyn
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022468 or its brand name (Folotyn, Pralatrexate). Reports on generic versions are filed under their own applications.
Reports
650
Serious
603
93% of reports
Hospitalization
259
Death reported
164
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- malignant neoplasm progression118
- stomatitis103
- disease progression71
- mucosal inflammation64
- platelet count decreased57
- pyrexia51
- anaemia49
- neutrophil count decreased42
- drug ineffective41
- febrile neutropenia39
- neutropenia34
- off label use33
- thrombocytopenia33
- death32
- diarrhoea25
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2010 | 31 |
| 2011 | 33 |
| 2012 | 38 |
| 2013 | 37 |
| 2014 | 15 |
| 2015 | 24 |
| 2016 | 29 |
| 2017 | 24 |
| 2018 | 46 |
| 2019 | 43 |
| 2020 | 62 |
| 2021 | 105 |
| 2022 | 59 |
| 2023 | 35 |
| 2024 | 24 |
| 2025 | 33 |
| 2026 | 12 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,509 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| mucosal inflammationSignal | 64 | 79.3 | 62.8 | 4,864 |
| stomatitisSignal | 103 | 55.0 | 46.1 | 5,418 |
| malignant neoplasm progressionSignal | 118 | 37.3 | 31.7 | 4,151 |
| neutrophil count decreasedSignal | 42 | 33.4 | 24.9 | 1,288 |
| disease progressionSignal | 71 | 19.4 | 15.6 | 1,229 |
| febrile neutropeniaSignal | 39 | 19.0 | 14.0 | 650 |
| platelet count decreasedSignal | 57 | 17.3 | 13.5 | 864 |
| thrombocytopeniaSignal | 33 | 9.6 | 6.8 | 245 |
| anaemiaSignal | 49 | 8.3 | 6.4 | 311 |
| neutropeniaSignal | 34 | 8.1 | 5.8 | 206 |
| pyrexiaSignal | 51 | 4.8 | 3.7 | 151 |
| diarrhoea | 25 | 1.3 | 0.9 | 1 |
| off label use | 33 | 1.2 | 0.9 | 1 |
| death | 32 | 1.2 | 0.9 | 1 |
| drug ineffective | 41 | 1.0 | 0.7 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.